PeptiDream : Financial Results Presentation (First Half of the Fiscal Year Ending December 2022) (3MB）
August 09, 2022 at 06:46 am EDT
Share
The Second Quarter of Fiscal Year Ending December 31, 2022
Financial Results Presentation
August 10, 2022
PeptiDream Inc.
(TSE : 4587)
Table of Contents
Outline of Consolidated FY2022 Q2 Financial Results
Progress of Key R&D Programs and Future Development Plan
Q&A
2
The Second Quarter of Fiscal Year Ending December 31, 2022
1 Outline of Consolidated Financial Results
3
Network of Strategic Investments and Affiliated Companies
Expanding PeptiDream's growth platform by strengthening our network of partners
<15%
Growing reputation as a high-quality manufacturer of GLP/GMP grade peptides
Peptide-CDMO
Business
(2017-)
39.5%
5% Strategic partner in the discovery and development of RI-PDC products
• Lead program scheduled to enter GLP-IND stage in 2022
Radiopharma
• PeptiDream has an option to develop and
commercialize the joint programs in Japan
Business
(2020-)
<5%
Computer aided small molecule drug
Development and commercialization of peptide alternatives to growth factors, and R&D collaborations for therapeutic use
Two products launched in 2021
Two additional products launched to date in 2022
Growth Factor
Business
(2020-)
39.4%
Computational
Drug Discovery
(2018-)
Radiopharma
development of allosteric kinase inhibitors by using peptide starting points
Lead program scheduled to enter GLP-IND stage in 2022
100%
Established platform for clinical development, approval, marketing and sales of radiopharmaceuticals in Japan
• Acquisition completed on
Advancing potent CoV2 antagonist PA-001 in clinical development
COVID-19
Therapeutics
(2020-)
Business (2022-)
Mar 28, 2022
• Transforming into a
quickly profitable, high-
growth model
Note: The year PeptiDream made investment
4
Consolidated / Equity Method Applied Companies in Our Group
Rolling out "2 Segments, 4 Business Strategies" in consolidation accounting from FY2022
Parent
company
Subsidiary
Consolidation Accounting
Drug Discovery and
Radiopharmaceutical
1
Development
2
Business Segment
Business Segment
1 Collaboration on Drug
Discovery and Development
2 PDPS Technology Licensing
Strategic Alliance/
3 In-House Program
Radiopharma
4
R&D, Manufacturing
and Sales of
100%
Business
Radiopharmaceuticals
(2022-)
EquityMethod Accounting
Share of profit (loss) of investments accounted for using equity method recorded as non-operating income or loss
Affiliated
Companies
39.5%
Growth Factor
COVID-19
Business
Therapeutics
39.4%
(2020-)
(2020-)
Note: Increase or decrease in the value of our shares is recorded as comprehensive income or loss, for PeptiStar, RayzeBio and Modulus.
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
PeptiDream Inc. published this content on 09 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 August 2022 10:45:01 UTC.
PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).
PEPTIDREAM INC. 
